Vsv chimeric vectors
AssigneesVira Therapeutics GmbH, Boehringer Ingelheim International GmbH
InventorsTobias NOLDEN, Patrik ERLMANN, Guido WOLLMANN, Zoltan BANKI, Bart SPIESSCHAERT, Janine KIMPEL, Dorothee VON LAER
Life of this patent
Estimating the term…
Abstract
The present invention relates to VSV chimeric vectors, characterized in that the vectors comprise a gene coding for a glycoprotein GP of the Dandenong virus (DANDV) or Mopeia vims (MOPV) and lack a functional gene coding for envelope protein G of the VSV. The invention also provides VSV chimeric vector systems. In addition, the invention relates to uses of the VSV chimeric vectors and systems of the invention, including the use in medicine such as in the treatment of solid tumors.
Claims22
VSV chimeric vector, characterized in that the vector comprises a gene coding for a glycoprotein GP of the Dandenong virus or Mopeia virus and lacks a functional gene coding for envelope protein G of the VSV.
VSV chimeric vector system, characterized in that the system comprises at least two complementary replicating VSV vectors, wherein the system comprises genes n, l, p and m coding for proteins N, L, P and M of the VSV, a gene gp coding for Dandenong-GP or Mopeia-GP and lacks a functional gene coding for G protein of the VSV, wherein each vector of the system lacks one of the genes n, l, p, m and gp, and wherein the lacking gene is present on any other vector of the system.
Chimeric VSV virion, characterized in that the virion comprises a GP protein of the Dandenong or Mopeia virus as envelope protein.
Dependencies are inferred from the claim text.